MOS-118

MOS-118 is a small molecule drug developed as a nasal spray for the treatment of obstructive sleep apnea (OSA), specifically targeting metabolic OSA. Originally known as AVE 0118 and developed by Sanofi-Aventis for cardiac arrhythmias, it is now being advanced by Mosanna Therapeutics. The drug works by modulating potassium channels in the upper airway muscles to restore the body's natural airway reflex, thereby preventing airway collapse during sleep. This approach treats OSA as a neurological and muscular dysfunction rather than solely a mechanical issue. The formulation is designed for local delivery via nasal spray at bedtime, aiming to improve adherence and outcomes compared to traditional mechanical treatments like CPAP[1][2][3][4][6][9].

Other names

MOS 118MOS118MOS-118AVE 0118AVE0118AVE-0118